1-8 of 8
Ivan Bergstein, MD
Close
Sort by
Journal Articles

Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Anthony S. Stein, MD, Sumithira Vasu, MD MBBS, William Blum, MD, David A. Rizzieri, MD, Eunice S. Wang, MD, Madeleine Duvic, MD, Sharon Spence, Shay Shemesh, Christopher Brooks, PhD, Ivan Bergstein, MD, Janice Chen, PhD, Vanessa Dunn, Peter McDonald, John Mark Sloan, MD, Jeffrey E. Lancet, MD, Hagop M. Kantarjian, MD, Marina Y. Konopleva, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 765.
https://doi.org/10.1182/blood-2018-99-118966
Published: 2018
Journal Articles

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Kendra L. Sweet, MD, Andrew A. Lane, MD PhD, Anthony S. Stein, MD, Sumithira Vasu, MDMBBS, William Blum, MD, David A. Rizzieri, MD, Eunice S. Wang, MD, Madeleine Duvic, MD, Phyu Aung, MD, Danielle Shubert, Sharon Spence, Shay Shemesh, Janice Chen, PhD, Christopher Brooks, PhD, Ivan Bergstein, MD, Peter McDonald, Trishna Goswami, MD, John Mark Sloan, MD, Jeffrey E. Lancet, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1298.
https://doi.org/10.1182/blood.V130.Suppl_1.1298.1298
Published: 2017
Journal Articles

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia

Christopher Brooks, PhD, Janice Chen, PhD, David M. Lucas, PhD, Natarajan Muthusamy, DVM, PhD, Ivan Bergstein, MD, Eric Rowinsky, MD
Journal: Blood
Blood (2014) 124 (21): 5663.
https://doi.org/10.1182/blood.V124.21.5663.5663
Published: 2014
Journal Articles

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Arthur E. Frankel, MD, Jung H. Woo, PhD, Jeremy P. Mauldin, PhD, Hetty E. Carraway, MD, MBA, Olga Frankfurt, MD, Stephen J. Forman, MD, Sumithira Vasu, MBBS, Naveen Pemmaraju, MD, Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, Francine Garanache-Ottou, Ph.D., Fanny Angelot-Delettre, PhD, Christopher Brooks, PhD, Michael Szarek, PhD, Ivan Bergstein, MD, Eric Rowinsky, MD
Journal: Blood
Blood (2013) 122 (21): 2682.
https://doi.org/10.1182/blood.V122.21.2682.2682
Published: 2013
Journal Articles

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

Christopher Brooks, PhD, Vincent Macri, Arnaldo Albini, MD, Ivan Bergstein, MD, Eric Rowinsky, MD
Journal: Blood
Blood (2013) 122 (21): 4104.
https://doi.org/10.1182/blood.V122.21.4104.4104
Published: 2013
Journal Articles

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, David A. Rizzieri, MD, Thomas P. Cirrito, PhD, Steven M. Kornblau, MD, PhD, Gautam Borthakur, M.D., Carol Bivins, RN, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Farhad Ravandi, MD, Michael Andreeff, MD, PhD, Jorge E. Cortes, MD, Kenneth Hoberman, Michael Szarek, PhD, Eric Rowinsky, MD, Ivan Bergstein, MD, Hagop M. Kantarjian, MD, Arthur E. Frankel, MD
Journal: Blood
Blood (2012) 120 (21): 3625.
https://doi.org/10.1182/blood.V120.21.3625.3625
Published: 2012
Journal Articles

Hodgkin's Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,

Catherine S. Diefenbach, MD, Rachel Sabado, PhD, Christopher L. Brooks, PhD, Jairo Baquero-Buitrago, MSc, Crystal Cruz, Isabelita Vengco, Francesca Montanari, MD, Enrica Marchi, MD, Ph.D., Luigi Scotto, Ph.D., Thomas P. Cirrito, PhD, Ivan Bergstein, MD, Owen A. O'Connor, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3737.
https://doi.org/10.1182/blood.V118.21.3737.3737
Published: 2011
Journal Articles

Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS

Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, David A. Rizzieri, MD, Thomas P. Cirrito, PhD, Jen Sing Liu, PhD, Steven M. Kornblau, MD, Margarite Grable, Il-Ran Hwang, Gautam Borthakur, MD, Allison Mankin, Carol Bivins, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, David Harris, Farhad Ravandi, MD, Michael Andreeff, MD, PhD, Jorge E. Cortes, Robert Niecestro, PhD, Ivan Bergstein, MD, Hagop M. Kantarjian, MD, Arthur E. Frankel, MD
Journal: Blood
Blood (2010) 116 (21): 3298.
https://doi.org/10.1182/blood.V116.21.3298.3298
Published: 2010